Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA

NCT03314051 is registered in ClinicalTrials.gov with Taichung Veterans General Hospital as lead sponsor.

NCT NCT03314051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA
Lead sponsor
Taichung Veterans General Hospital
Phase
Observational
Overall status
Completed
Start date
May 2, 2012
Completion date
December 31, 2016
Enrollment
366 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ebv related carcinoma, nasopharyngeal carcinoma